Galectin Therapeutics (GALT)
Galectin Therapeutics on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
9.1M
Short interest
settlement 2026-10-15
40.0
Days to cover
+6.3 days vs prior
44.2%
Short share of volume
2026-11-03
2,828
Fails to deliver
settlement 2026-10-14
Fri 13 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-11-03.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in GALT is 9,130,477 shares, down 204,828 shares over the last month. Over the last 48 readings it ranged from 4,749,085 shares (15 January 2026) to 9,335,305 shares (15 September 2026). The latest reading sits at the top of that range. At the reported average volume of 228K shares a day that is 40.0 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/galt" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 9,130,477 | -0.8% | 228,416 | 39.97 |
| 2026-09-30 | 9,206,832 | -1.4% | 273,539 | 33.66 |
| 2026-09-15 | 9,335,305 | +2.9% | 371,026 | 25.16 |
| 2026-08-31 | 9,075,436 | +0.8% | 272,112 | 33.35 |
| 2026-08-14 | 9,002,474 | +3.5% | 417,100 | 21.58 |
| 2026-07-31 | 8,696,498 | +2.4% | 367,988 | 23.63 |
| 2026-07-15 | 8,494,056 | -5.3% | 753,508 | 11.27 |
| 2026-06-30 | 8,972,735 | +14.1% | 1,841,200 | 4.87 |
| 2026-06-15 | 7,866,406 | +2.6% | 250,817 | 31.36 |
| 2026-05-29 | 7,663,672 | +4.1% | 388,753 | 19.71 |
| 2026-05-15 | 7,359,773 | -0.4% | 345,559 | 21.30 |
| 2026-04-30 | 7,388,749 | -1.0% | 299,033 | 24.71 |
| 2026-04-15 | 7,462,075 | +9.7% | 400,423 | 18.64 |
| 2026-03-31 | 6,801,737 | +3.6% | 232,219 | 29.29 |
| 2026-03-13 | 6,567,660 | +27.1% | 479,761 | 13.69 |
| 2026-02-27 | 5,169,383 | +1.5% | 193,806 | 26.67 |
| 2026-02-13 | 5,093,508 | +6.2% | 278,705 | 18.28 |
| 2026-01-30 | 4,797,622 | +1.0% | 316,060 | 15.18 |
| 2026-01-15 | 4,749,085 | -3.1% | 510,379 | 9.31 |
| 2025-12-31 | 4,902,530 | -17.6% | 890,925 | 5.50 |
| 2025-12-15 | 5,950,487 | -12.7% | 623,168 | 9.55 |
| 2025-11-28 | 6,816,789 | +0.9% | 295,373 | 23.08 |
| 2025-11-14 | 6,757,137 | -2.1% | 435,391 | 15.52 |
| 2025-10-31 | 6,903,772 | -17.7% | 348,046 | 19.84 |
| 2025-10-15 | 8,385,038 | +2.1% | 278,157 | 30.14 |
| 2025-09-30 | 8,212,706 | +2.1% | 231,839 | 35.42 |
| 2025-09-15 | 8,046,606 | +0.7% | 495,296 | 16.25 |
| 2025-08-29 | 7,990,039 | +0.3% | 197,427 | 40.47 |
| 2025-08-15 | 7,963,539 | +3.3% | 279,416 | 28.50 |
| 2025-07-31 | 7,708,146 | +0.1% | 316,532 | 24.35 |
| 2025-07-15 | 7,696,871 | -1.2% | 367,275 | 20.96 |
| 2025-06-30 | 7,788,885 | -13.0% | 2,647,488 | 2.94 |
| 2025-06-13 | 8,954,593 | +0.6% | 155,109 | 57.73 |
| 2025-05-30 | 8,901,607 | +2.7% | 175,938 | 50.60 |
| 2025-05-15 | 8,667,591 | +2.3% | 165,969 | 52.22 |
| 2025-04-30 | 8,469,618 | +1.4% | 110,919 | 76.36 |
| 2025-04-15 | 8,355,868 | +5.9% | 260,197 | 32.11 |
| 2025-03-31 | 7,892,362 | -3.2% | 345,555 | 22.84 |
| 2025-03-14 | 8,154,175 | +0.4% | 187,946 | 43.39 |
| 2025-02-28 | 8,120,001 | +5.1% | 271,492 | 29.91 |
| 2025-02-14 | 7,723,114 | -3.2% | 273,744 | 28.21 |
| 2025-01-31 | 7,976,945 | -2.2% | 242,512 | 32.89 |
| 2025-01-15 | 8,156,146 | +1.5% | 470,828 | 17.32 |
| 2024-12-31 | 8,037,067 | -2.8% | 2,339,542 | 3.44 |
| 2024-12-13 | 8,269,328 | +41.2% | 811,167 | 10.19 |
| 2024-11-29 | 5,857,911 | +2.7% | 189,865 | 30.85 |
| 2024-11-15 | 5,702,047 | +3.4% | 166,741 | 34.20 |
| 2024-10-31 | 5,517,314 | +1.1% | 127,562 | 43.25 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 3 November 2026, the short share of GALT volume is 44.2%, down 13.0 points over the last five sessions. Over the last 30 readings it ranged from 28.6% (22 October 2026) to 78.4% (8 October 2026). The latest reading is 5.7 points below the 30-session average of 49.9%, on 48K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-03 | 21K | 48K | 44.2% | 0 |
| 2026-11-02 | 14K | 35K | 41.2% | 0 |
| 2026-10-30 | 37K | 74K | 50.6% | 0 |
| 2026-10-29 | 86K | 113K | 75.8% | 400 |
| 2026-10-28 | 22K | 48K | 46.1% | 0 |
| 2026-10-27 | 51K | 89K | 57.1% | 142 |
| 2026-10-26 | 39K | 75K | 52.3% | 2 |
| 2026-10-23 | 42K | 95K | 44.2% | 0 |
| 2026-10-22 | 17K | 60K | 28.6% | 0 |
| 2026-10-21 | 67K | 131K | 51.4% | 898 |
| 2026-10-20 | 43K | 89K | 48.3% | 0 |
| 2026-10-19 | 31K | 79K | 40.0% | 0 |
| 2026-10-16 | 41K | 74K | 55.5% | 0 |
| 2026-10-15 | 30K | 64K | 46.2% | 264 |
| 2026-10-14 | 110K | 269K | 40.7% | 0 |
| 2026-10-13 | 39K | 78K | 50.8% | 0 |
| 2026-10-12 | 23K | 43K | 53.1% | 231 |
| 2026-10-09 | 50K | 72K | 69.7% | 0 |
| 2026-10-08 | 60K | 77K | 78.4% | 300 |
| 2026-10-07 | 35K | 68K | 51.6% | 61 |
| 2026-10-06 | 55K | 124K | 44.2% | 0 |
| 2026-10-05 | 39K | 126K | 30.7% | 4,148 |
| 2026-10-02 | 49K | 96K | 51.1% | 0 |
| 2026-10-01 | 60K | 152K | 39.8% | 1 |
| 2026-09-30 | 29K | 72K | 40.9% | 200 |
| 2026-09-29 | 53K | 91K | 57.9% | 126 |
| 2026-09-28 | 28K | 61K | 46.7% | 4,874 |
| 2026-09-25 | 27K | 46K | 59.5% | 0 |
| 2026-09-24 | 31K | 61K | 50.0% | 0 |
| 2026-09-23 | 37K | 72K | 50.9% | 100 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 14 October 2026, the fails-to-deliver balance in GALT is 2,828 shares, down 7,052 shares over the last settlement date. Over the last 30 readings it ranged from 108 shares (28 September 2026) to 57,461 shares (24 August 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-14 | 2,828 | $3.69 | $10K |
| 2026-10-13 | 9,880 | $3.87 | $38K |
| 2026-10-08 | 2,396 | $3.62 | $9K |
| 2026-10-07 | 5,823 | $3.76 | $22K |
| 2026-10-01 | 2,156 | $3.88 | $8K |
| 2026-09-29 | 334 | $3.93 | $1K |
| 2026-09-28 | 108 | $3.90 | $421 |
| 2026-09-25 | 6,925 | $3.96 | $27K |
| 2026-09-24 | 3,074 | $4.05 | $12K |
| 2026-09-22 | 12,007 | $3.96 | $48K |
| 2026-09-18 | 2,845 | $3.71 | $11K |
| 2026-09-17 | 1,083 | $3.68 | $4K |
| 2026-09-16 | 1,488 | $3.73 | $6K |
| 2026-09-15 | 555 | $3.84 | $2K |
| 2026-09-14 | 11,774 | $3.91 | $46K |
| 2026-09-11 | 2,077 | $3.90 | $8K |
| 2026-09-10 | 186 | $4.05 | $753 |
| 2026-09-09 | 11,554 | $4.14 | $48K |
| 2026-09-08 | 10,585 | $4.61 | $49K |
| 2026-09-01 | 2,231 | $3.95 | $9K |
| 2026-08-31 | 4,435 | $4.02 | $18K |
| 2026-08-27 | 17,507 | $4.15 | $73K |
| 2026-08-26 | 23,284 | $3.99 | $93K |
| 2026-08-25 | 28,763 | $3.88 | $112K |
| 2026-08-24 | 57,461 | $3.68 | $211K |
| 2026-08-21 | 797 | $3.57 | $3K |
| 2026-08-20 | 2,023 | $3.67 | $7K |
| 2026-08-19 | 7,455 | $3.52 | $26K |
| 2026-08-18 | 1,533 | $3.51 | $5K |
| 2026-08-14 | 35,979 | $3.53 | $127K |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for GALT in the last 90 days. The most recent filings are listed below. Latest filing: Uihlein Richard E (Director, 10% owner) on 2026-07-31.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-07-31 | Uihlein Richard E | Director, 10% owner | Exercise or conversion | 2.6M | $4.05 | $10.3M | 44.7M |
| 2026-07-31 | Uihlein Richard E | Director, 10% owner | Exercise or conversion | 31.8M | $3.00 | $95.5M | 42.2M |
| 2026-07-14 | Jamil Khurram | Chief Medical Officer | Sell | 16K | $5.13 | $83K | 0 |
| 2026-07-14 | Jamil Khurram | Chief Medical Officer | Exercise or conversion | 16K | $3.04 | $49K | 16K |
| 2026-06-29 | Jamil Khurram | Chief Medical Officer | Exercise or conversion | 47K | $2.50 | $119K | 47K |
| 2026-06-29 | Jamil Khurram | Chief Medical Officer | Sell | 47K | $5.04 | $239K | 0 |
| 2026-06-29 | Shlevin Harold H. | Director | Exercise or conversion | 22K | $1.23 | $27K | 29K |
| 2026-06-29 | Shlevin Harold H. | Director | Sell | 22K | $5.04 | $112K | 7K |
| 2026-06-26 | Jamil Khurram | Chief Medical Officer | Exercise or conversion | 3K | $2.50 | $6K | 3K |
| 2026-06-26 | Jamil Khurram | Chief Medical Officer | Sell | 3K | $5.00 | $13K | 0 |
| 2026-06-26 | Jamil Khurram | Chief Medical Officer | Sell | 2K | $5.00 | $10K | 0 |
| 2026-06-26 | Jamil Khurram | Chief Medical Officer | Exercise or conversion | 2K | $2.20 | $4K | 2K |
| 2026-06-26 | Shlevin Harold H. | Director | Sell | 8K | $5.00 | $39K | 7K |
| 2026-06-26 | Shlevin Harold H. | Director | Exercise or conversion | 8K | $1.23 | $10K | 14K |
| 2026-06-23 | Jamil Khurram | Chief Medical Officer | Sell | 8K | $3.14 | $24K | 0 |
| 2026-06-23 | Jamil Khurram | Chief Medical Officer | Exercise or conversion | 8K | $1.23 | $9K | 8K |
| 2026-05-26 | Jamil Khurram | Chief Medical Officer | Sell | 568 | $3.10 | $2K | 0 |
| 2026-05-26 | Jamil Khurram | Chief Medical Officer | Exercise or conversion | 568 | $1.23 | $699 | 568 |
| 2026-02-06 | ELDRED KARY | Director | Buy | 300 | $2.70 | $810 | 66K |
| 2026-01-16 | Uihlein Richard E | Director, 10% owner | Grant | 13K | $3.04 | $40K | 10.3M |
| 2026-01-06 | LEWIS JOEL | President and CEO | Sell | 38K | $3.58 | $135K | 833K |
| 2026-01-06 | Jamil Khurram | Chief Medical Officer | Sell | 21K | $3.65 | $78K | 0 |
| 2026-01-06 | CALLICUTT JACK W | Chief Financial Officer | Sell | 20K | $3.67 | $75K | 8K |
| 2026-01-05 | LEWIS JOEL | President and CEO | Sell | 28K | $3.91 | $108K | 870K |
| 2026-01-05 | Jamil Khurram | Chief Medical Officer | Sell | 25K | $3.90 | $99K | 21K |
| 2026-01-05 | CALLICUTT JACK W | Chief Financial Officer | Sell | 26K | $3.90 | $100K | 28K |
| 2026-01-05 | LEWIS JOEL | President and CEO | Other | 56K | $3.88 | $219K | 776K |
| 2026-01-02 | LEWIS JOEL | President and CEO | Sell | 19K | $4.20 | $78K | 898K |
| 2026-01-02 | LEWIS JOEL | President and CEO | Exercise or conversion | 84K | $0.00 | $0 | 917K |
| 2026-01-02 | Jamil Khurram | Chief Medical Officer | Sell | 13K | $4.20 | $55K | 47K |
| 2026-01-02 | Jamil Khurram | Chief Medical Officer | Exercise or conversion | 60K | $0.00 | $0 | 60K |
| 2026-01-02 | CALLICUTT JACK W | Chief Financial Officer | Sell | 14K | $4.20 | $58K | 54K |
| 2026-01-02 | CALLICUTT JACK W | Chief Financial Officer | Exercise or conversion | 60K | $0.00 | $0 | 68K |
| 2025-12-31 | Jamil Khurram | Chief Medical Officer | Sell | 8K | $4.07 | $33K | 0 |
| 2025-12-31 | Jamil Khurram | Chief Medical Officer | Exercise or conversion | 8K | $1.23 | $10K | 8K |
| 2025-12-23 | FREEMAN KEVIN D | Director | Buy | 6K | $3.55 | $20K | 55K |
| 2025-12-23 | FREEMAN KEVIN D | Director | Buy | 6K | $3.55 | $20K | 55K |
| 2025-12-23 | ELDRED KARY | Director | Buy | 700 | $3.73 | $3K | 65K |
| 2025-12-17 | LEWIS JOEL | President and CEO | Sell | 8K | $7.06 | $55K | 833K |
| 2025-12-17 | LEWIS JOEL | President and CEO | Exercise or conversion | 8K | $2.86 | $22K | 840K |
| 2025-12-17 | Jamil Khurram | Chief Medical Officer | Sell | 9K | $7.04 | $60K | 0 |
| 2025-12-17 | Jamil Khurram | Chief Medical Officer | Exercise or conversion | 9K | $2.50 | $21K | 9K |
| 2025-12-17 | Jamil Khurram | Chief Medical Officer | Sell | 6K | $7.04 | $45K | 0 |
| 2025-12-17 | Jamil Khurram | Chief Medical Officer | Exercise or conversion | 6K | $2.20 | $14K | 6K |
| 2025-12-17 | Jamil Khurram | Chief Medical Officer | Sell | 4K | $7.04 | $32K | 0 |
| 2025-12-17 | Shlevin Harold H. | Director | Sell | 5K | $7.04 | $33K | 7K |
| 2025-12-17 | Shlevin Harold H. | Director | Sell | 20K | $7.04 | $139K | 11K |
| 2025-12-17 | Shlevin Harold H. | Director | Exercise or conversion | 20K | $1.98 | $40K | 31K |
| 2025-12-16 | CZIRR JAMES C | TenPercentOwner | Sell | 31K | $6.66 | $204K | 5.6M |
| 2025-12-15 | Shlevin Harold H. | Director | Sell | 8K | $6.30 | $53K | 11K |
| 2025-12-15 | Shlevin Harold H. | Director | Exercise or conversion | 8K | $4.16 | $35K | 20K |
| 2025-12-12 | Shlevin Harold H. | Director | Sell | 20K | $6.27 | $124K | 11K |
| 2025-12-12 | Shlevin Harold H. | Director | Exercise or conversion | 20K | $4.16 | $82K | 31K |
| 2025-12-09 | Shlevin Harold H. | Director | Sell | 17K | $6.27 | $105K | 11K |
| 2025-12-09 | Shlevin Harold H. | Director | Exercise or conversion | 17K | $4.16 | $70K | 28K |
| 2025-12-08 | Shlevin Harold H. | Director | Sell | 20K | $6.00 | $120K | 11K |
| 2025-12-08 | Shlevin Harold H. | Director | Exercise or conversion | 20K | $1.11 | $22K | 31K |
| 2025-12-08 | Shlevin Harold H. | Director | Sell | 35K | $6.02 | $211K | 11K |
| 2025-12-08 | Shlevin Harold H. | Director | Exercise or conversion | 35K | $2.11 | $74K | 46K |
| 2025-12-08 | Shlevin Harold H. | Director | Sell | 20K | $5.96 | $119K | 11K |
| 2025-12-08 | Shlevin Harold H. | Director | Exercise or conversion | 20K | $1.98 | $40K | 31K |
| 2025-12-08 | Shlevin Harold H. | Director | Sell | 25K | $5.95 | $149K | 11K |
| 2025-12-08 | Shlevin Harold H. | Director | Exercise or conversion | 25K | $1.72 | $43K | 36K |
| 2025-12-08 | Shlevin Harold H. | Director | Sell | 20K | $5.96 | $119K | 11K |
| 2025-12-08 | Shlevin Harold H. | Director | Exercise or conversion | 20K | $2.11 | $42K | 31K |
| 2025-12-08 | Shlevin Harold H. | Director | Sell | 35K | $5.95 | $208K | 11K |
| 2025-12-08 | Shlevin Harold H. | Director | Exercise or conversion | 35K | $2.86 | $100K | 46K |
| 2025-12-08 | Shlevin Harold H. | Director | Sell | 4K | $6.00 | $24K | 11K |
| 2025-12-03 | 10X Capital Management, LLC | TenPercentOwner | Sell | 120K | $5.73 | $688K | 5.7M |
| 2025-12-03 | 10X Capital Management, LLC | TenPercentOwner | Sell | 132K | $5.73 | $757K | 5.7M |
| 2025-12-03 | 10X Fund, L.P. | 10% owner | Sell | 120K | $5.73 | $688K | 5.7M |
| 2025-12-02 | 10X Capital Management, LLC | TenPercentOwner | Sell | 30K | $5.47 | $164K | 5.8M |
| 2025-12-02 | 10X Fund, L.P. | 10% owner | Sell | 30K | $5.47 | $164K | 5.8M |
| 2025-11-24 | CZIRR JAMES C | TenPercentOwner | Other transaction | 24K | price not stated in the filing | not stated | 5.6M |
| 2025-11-18 | LEWIS JOEL | President and CEO | Sell | 7K | $6.15 | $42K | 833K |
| 2025-11-18 | LEWIS JOEL | President and CEO | Exercise or conversion | 7K | $2.39 | $16K | 839K |
| 2025-11-18 | CALLICUTT JACK W | Chief Financial Officer | Sell | 18K | $6.22 | $113K | 8K |
| 2025-11-18 | CALLICUTT JACK W | Chief Financial Officer | Exercise or conversion | 18K | $1.11 | $20K | 26K |
| 2025-11-18 | CALLICUTT JACK W | Chief Financial Officer | Sell | 28K | $6.22 | $175K | 8K |
| 2025-11-18 | CALLICUTT JACK W | Chief Financial Officer | Exercise or conversion | 28K | $1.98 | $56K | 36K |
| 2025-11-17 | LEWIS JOEL | President and CEO | Sell | 16K | $6.04 | $95K | 833K |
| 2025-11-17 | LEWIS JOEL | President and CEO | Exercise or conversion | 16K | $2.39 | $37K | 848K |
| 2025-11-17 | CALLICUTT JACK W | Chief Financial Officer | Sell | 2K | $6.03 | $14K | 8K |
| 2025-11-17 | CALLICUTT JACK W | Chief Financial Officer | Exercise or conversion | 2K | $1.23 | $3K | 10K |
| 2025-11-17 | CALLICUTT JACK W | Chief Financial Officer | Sell | 20K | $6.03 | $119K | 8K |
| 2025-11-17 | CALLICUTT JACK W | Chief Financial Officer | Exercise or conversion | 20K | $1.11 | $22K | 27K |
| 2025-11-17 | CALLICUTT JACK W | Chief Financial Officer | Sell | 10K | $6.03 | $58K | 8K |
| 2025-11-17 | CALLICUTT JACK W | Chief Financial Officer | Exercise or conversion | 10K | $1.98 | $19K | 17K |
| 2025-11-13 | Jamil Khurram | Chief Medical Officer | Sell | 42K | $5.47 | $227K | 4K |
| 2025-11-13 | Jamil Khurram | Chief Medical Officer | Exercise or conversion | 42K | $2.50 | $104K | 46K |
| 2025-11-13 | Jamil Khurram | Chief Medical Officer | Sell | 16K | $5.47 | $89K | 4K |
| 2025-11-13 | Jamil Khurram | Chief Medical Officer | Exercise or conversion | 16K | $1.23 | $20K | 21K |
| 2025-11-13 | Jamil Khurram | Chief Medical Officer | Sell | 42K | $5.47 | $227K | 4K |
| 2025-11-13 | Jamil Khurram | Chief Medical Officer | Exercise or conversion | 42K | $2.20 | $91K | 46K |
| 2025-11-13 | Jamil Khurram | Chief Medical Officer | Sell | 22K | $5.47 | $120K | 4K |
| 2025-11-11 | 10X Capital Management, LLC | TenPercentOwner | Sell | 40K | $5.25 | $210K | 5.8M |
| 2025-11-11 | 10X Fund, L.P. | 10% owner | Sell | 40K | $5.25 | $210K | 5.8M |
| 2025-11-10 | LEWIS JOEL | President and CEO | Sell | 2K | $6.03 | $11K | 833K |
| 2025-11-10 | LEWIS JOEL | President and CEO | Exercise or conversion | 2K | $2.39 | $4K | 834K |
| 2025-11-10 | CALLICUTT JACK W | Chief Financial Officer | Sell | 2K | $6.03 | $10K | 8K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON17 Form 144 notices on file for GALT worth $6.3M at the prices reported; 0 in the last 90 days worth $0. Latest: Jamil Khurram filed on 2026-06-26 to sell 68,287 shares ($341K) from 2026-06-26.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-06-26 | Jamil KhurramOfficer | 68K | $341K | 0.104% | 2026-06-26 | Stifel Nicolaus & Company Inc |
| 2026-06-23 | Jamil KhurramOfficer | 8K | $26K | 0.012% | 2026-06-23 | Stifel Nicolaus & Company Inc |
| 2026-01-06 | Shlevin Harold H.Director | 442K | $1.8M | 0.685% | 2026-01-02 | Merill Lynch |
| 2026-01-05 | CALLICUTT JACK WOfficer | 60K | $252K | 0.093% | 2026-01-02 | Stifel Nicolaus & Company Inc |
| 2026-01-02 | LEWIS JOELOfficer | 84K | $353K | 0.130% | 2026-01-02 | Stifel Nicolaus & Company Inc |
| 2026-01-02 | Jamil KhurramOfficer | 60K | $252K | 0.093% | 2026-01-02 | Stifel Nicolaus & Company Inc |
| 2026-01-02 | CALLICUTT JACK WOfficer | 141K | $593K | 0.219% | 2026-01-02 | Stifel Nicolaus & Company Inc |
| 2025-12-31 | Jamil KhurramOfficer | 8K | $33K | 0.013% | 2025-12-31 | Stifel Nicolaus & Company Inc |
| 2025-12-17 | Jamil KhurramOfficer | 21K | $151K | 0.033% | 2025-12-17 | Stifel Nicolaus & Company Inc |
| 2025-12-17 | LEWIS JOELOfficer | 40K | $282K | 0.062% | 2025-12-17 | Stifel Nicolaus & Company Inc |
| 2025-12-17 | HAROLD SHLEVINDIRECTOR | 25K | $172K | 0.038% | 2025-12-17 | NEIL MEHTA |
| 2025-12-15 | HAROLD SHLEVINDIRECTOR | 20K | $123K | 0.031% | 2025-12-12 | NEIL MEHTA |
| 2025-12-15 | HAROLD SHLEVINDIRECTOR | 8K | $53K | 0.013% | 2025-12-15 | NEIL MEHTA |
| 2025-12-12 | HAROLD SHLEVINDIRECTOR | 20K | $123K | 0.031% | 2025-12-12 | NEIL MEHTA |
| 2025-12-09 | HAROLD SHLEVINDIRECTOR | 17K | $104K | 0.026% | 2025-12-09 | NEIL MEHTA |
| 2025-12-08 | HAROLD SHLEVINDIRECTOR | 159K | $957K | 0.247% | 2025-12-08 | NEIL MEHTA |
| 2025-11-13 | Jamil KhurramOfficer | 121K | $660K | 0.189% | 2025-11-13 | Stifel Nicolaus & Company Inc |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON1 holder reports 5% or more of GALT in its latest filing, on Schedule 13D (active intent). The holder is Richard E. Uihlein at 49.3% of the class (54,673,646 shares), filed 2026-08-04 for an event on 2026-07-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-04 | 13D/Ano. 2 | Richard E. Uihleinindividual | 54.7M | 49.3% | 2026-07-31 |
13F holders
Tracked managers holding GALT at their latest 13F. JSON4 of the 30 tracked managers held GALT at their latest 13F, $2.8M in total at quarter-end prices. Two Sigma Investments is the largest at $1.5M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 0 added shares and 4 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Two Sigma Investments | 2026-06-30 | 318K | $1.5M | 0.00% | -149K |
| Citadel Advisors | 2026-06-30 | 199K | $922K | 0.00% | -92K |
| Renaissance Technologies | 2026-06-30 | 43K | $201K | 0.00% | -105K |
| Millennium Management | 2026-06-30 | 36K | $166K | 0.00% | -763K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn FY 2025 it generated -$23.9M of operating cash flow.
- Cash
- $13.3M
- Equity
- -$138.6M
- Total assets
- $14.8M
- Shares outstanding
- 100,849,644
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | n/a | -$9.1M | n/a | -0.14 |
| Q1 FY 2026 | 2026-03-31 | n/a | -$5.0M | n/a | -0.08 |
| Q4 FY 2025derived | 2025-12-31 | n/a | -$5.5M | n/a | n/a |
| Q3 FY 2025 | 2025-09-30 | n/a | -$8.2M | n/a | -0.13 |
| Q2 FY 2025 | 2025-06-30 | n/a | -$7.5M | n/a | -0.12 |
| Q1 FY 2025 | 2025-03-31 | n/a | -$9.6M | n/a | -0.15 |
| Q4 FY 2024derived | 2024-12-31 | n/a | -$12.0M | n/a | n/a |
| Q3 FY 2024 | 2024-09-30 | n/a | -$11.2M | n/a | -0.18 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | n/a | -$30.8M | -$23.9M | n/a | n/a | n/a |
| FY 2024 | 2024-12-31 | n/a | -$47.0M | -$41.8M | n/a | n/a | n/a |
| FY 2023 | 2023-12-31 | n/a | -$41.1M | -$33.0M | n/a | n/a | n/a |
| FY 2022 | 2022-12-31 | n/a | -$38.8M | -$31.1M | n/a | n/a | n/a |
| FY 2021 | 2021-12-31 | n/a | -$30.5M | -$24.3M | n/a | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-08-06 from the cover page.
What this page is
Galectin Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Galectin Therapeutics (GALT), SEC CIK 1133416, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-03.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-14.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-06-26.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-04.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-14.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-07-31.JSON and CSV
- Company record
- EDGAR filing index for CIK 1133416Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
Datasets
Frequently Asked Questions
How much of GALT is sold short?
9,130,477 shares were held short at the 2026-10-15 settlement, 40.0 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is GALT's daily short volume?
On 2026-11-03, 21,263 of the 48,125 GALT shares reported to FINRA were sold short, 44.2% of the day's reported volume. Short volume is a flow for one day, not a position.
Does GALT have fails to deliver?
The SEC's latest file shows 2,828 GALT shares failed to deliver at settlement 2026-10-14. Fails are reported per settlement date and published twice a month with a lag.
Are GALT insiders buying or selling?
No open-market insider trades were reported for GALT in the last 90 days. The most recent filings are listed below. Latest filing: Uihlein Richard E (Director, 10% owner) on 2026-07-31.
Have GALT insiders filed to sell?
17 Form 144 notices on file for GALT worth $6.3M at the prices reported; 0 in the last 90 days worth $0. Latest: Jamil Khurram filed on 2026-06-26 to sell 68,287 shares ($341K) from 2026-06-26.
Who owns 5% or more of GALT?
1 holder reports 5% or more of GALT in its latest filing, on Schedule 13D (active intent). The holder is Richard E. Uihlein at 49.3% of the class (54,673,646 shares), filed 2026-08-04 for an event on 2026-07-31.
What did GALT report last quarter?
In FY 2025 it generated -$23.9M of operating cash flow.
Which tracked 13F managers own GALT?
4 of the 30 tracked 13F managers held GALT shares at their latest filing, $2.8M in all. The largest: Two Sigma Investments (318K shares, $1.5M), Ken Griffin's Citadel Advisors (199K shares, $922K), Renaissance Technologies (43K shares, $201K), Izzy Englander's Millennium Management (36K shares, $166K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.